What is the clinical evidence from this study?

Study design: Other. Population: Depression. Intervention: Venlafaxine, Duloxetine, Desvenlafaxine, Milnacipran, Levomilnacipran. Primary outcome: Long-term side effects of SNRI therapy in patients diagnosed with depression.

What question did this study set out to answer?

The study aims to systematically evaluate the long-term side effects of SNRI therapy in depressed patients.

March 13, 2026Open Access

Investigating Long-Term Side Effects of Snri: Venlafaxine, Duloxetine, Desvenlafaxine, Milnacipran, and Levomilnacipran Antidepressants Treatment in Patients Diagnosed With Depression

Q: What does this research mean for the field?

Chronic use of serotonin-norepinephrine reuptake inhibitors (SNRIs) is associated with significant long-term side effects, including metabolic, cardiovascular, and skeletal complications in patients diagnosed with depression. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Key Result

Prolonged SNRI therapy significantly increases the risk of hyponatremia, particularly in vulnerable populations, necessitating regular electrolyte monitoring during treatment.

Key Points

The study aims to systematically evaluate the long-term side effects of SNRI therapy in depressed patients.
Conducted a systematic literature review on SNRI side effects.
Focused on long-term adverse effects associated with prolonged usage.
Analyzed existing clinical guidelines and patient outcomes.
Identified common short-term effects like weight gain and sexual dysfunction.
Highlighted long-term complications including metabolic and cardiovascular issues.
Synthesized risk profiles for chronic SNRI use to inform clinical practices.

Structured PICO

What are the long-term adverse effects of SNRI therapy in patients diagnosed with depression?

Population

Patients diagnosed with depression receiving long-term SNRI therapy

Intervention

Long-term therapy with Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) including venlafaxine, duloxetine, desvenlafaxine, milnacipran, and levomilnacipran

Outcome

Long-term side effects of SNRI therapysafety

Long-term use of SNRIs for depression is associated with significant adverse effects, including hyponatremia, fractures, and cardiovascular risks, necessitating careful monitoring.

Limitations

The evidence is based on existing literature rather than a primary clinical study.

Abstract

Depression is a prevalent mental health disorder affecting approximately 4% of the global population. Pharmacological management commonly involves the use of serotonin–norepinephrine reuptake inhibitors (SNRIs), including venlafaxine, duloxetine, desvenlafaxine, milnacipran, and levomilnacipran. Although these agents are effective in alleviating depressive symptoms, their prolonged use raises concerns regarding long-term safety. Clinical guidelines recommend antidepressant (AD) therapy for at least six months following symptom remission after the first episode of major depression; however, in practice, treatment duration often extends for years. Extended exposure to SNRIs has been associated with both common short-term adverse effects—such as weight gain, appetite changes, and sexual dysfunction—and less understood long-term outcomes, including metabolic, cardiovascular, and skeletal complications. The objective of this study is to systematically evaluate existing literature on the long-term side effects of SNRI therapy in patients diagnosed with depression. By synthesizing current evidence, this review aims to enhance understanding of the risk profile associated with chronic SNRI use and inform safer clinical practices.

Bookmark

View Full Paper